Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Pharma Industry Analysis

UpdatedDec 23, 2025
DataAggregated Company Financials
Companies23
  • 7D0.02%
  • 3M-10.2%
  • 1Y-1.7%
  • YTD-4.0%

Over the last 7 days, the Pharma industry has remained flat, although notably Swedencare gained 5.2%. Furthermore, the industry has been flat for the past year as well. As for the next few years, earnings are expected to grow by 39% per annum.

Industry Valuation and Performance

Has the Swedish Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 24 Dec 2025SEK 49.4bSEK 5.3b-SEK 531,735,157.0072.2x-92.9x9.3x
Fri, 21 Nov 2025SEK 49.6bSEK 5.3b-SEK 522,560,865.0069.6x-94.9x9.4x
Sun, 19 Oct 2025SEK 53.3bSEK 5.1b-SEK 405,183,865.0068x-131.5x10.5x
Tue, 16 Sep 2025SEK 55.9bSEK 5.1b-SEK 405,183,865.0077.2x-138x11x
Thu, 14 Aug 2025SEK 52.5bSEK 5.1b-SEK 318,692,364.0071.7x-164.6x10.4x
Sat, 12 Jul 2025SEK 56.4bSEK 4.8b-SEK 525,205,364.0077.4x-107.3x11.8x
Mon, 09 Jun 2025SEK 52.8bSEK 4.8b-SEK 574,396,765.4470.4x-91.9x10.9x
Wed, 07 May 2025SEK 54.0bSEK 4.8b-SEK 940,638,233.7879.3x-57.4x11.3x
Fri, 04 Apr 2025SEK 47.8bSEK 4.7b-SEK 809,145,235.3968.6x-59x10.2x
Sun, 02 Mar 2025SEK 54.7bSEK 4.7b-SEK 763,977,212.7079.6x-71.6x11.7x
Tue, 28 Jan 2025SEK 49.8bSEK 4.4b-SEK 810,061,268.90123.4x-61.4x11.2x
Thu, 26 Dec 2024SEK 50.1bSEK 4.4b-SEK 615,911,477.26125.3x-81.3x11.3x
Sat, 23 Nov 2024SEK 50.3bSEK 4.4b-SEK 620,717,014.43126.6x-81x11.3x
Mon, 21 Oct 2024SEK 53.9bSEK 4.3b-SEK 677,083,649.86136.8x-79.6x12.6x
Wed, 18 Sep 2024SEK 66.5bSEK 5.9b-SEK 1,169,918,052.73174.4x-56.9x11.3x
Fri, 16 Aug 2024SEK 69.0bSEK 5.9b-SEK 946,972,901.7887x-72.9x11.7x
Sun, 14 Jul 2024SEK 69.5bSEK 6.4b-SEK 835,140,932.6385.7x-83.2x10.9x
Tue, 11 Jun 2024SEK 61.9bSEK 6.5b-SEK 918,958,027.6575.2x-67.4x9.6x
Thu, 09 May 2024SEK 51.2bSEK 6.4b-SEK 803,411,939.1268.4x-63.8x8x
Sat, 06 Apr 2024SEK 51.4bSEK 6.2b-SEK 1,038,130,822.6777.9x-49.6x8.2x
Mon, 04 Mar 2024SEK 47.5bSEK 6.2b-SEK 1,038,034,450.5779.1x-45.8x7.6x
Wed, 31 Jan 2024SEK 69.9bSEK 9.5b-SEK 1,181,796,965.0067.1x-59.2x7.4x
Fri, 29 Dec 2023SEK 68.6bSEK 9.4b-SEK 1,184,200,355.0065x-58x7.3x
Sun, 26 Nov 2023SEK 61.2bSEK 9.5b-SEK 1,174,445,030.0054.4x-52.1x6.5x
Tue, 24 Oct 2023SEK 50.4bSEK 9.2b-SEK 1,143,058,911.00104.7x-44.1x5.5x
Thu, 21 Sep 2023SEK 51.2bSEK 9.2b-SEK 1,177,907,877.00134.3x-43.4x5.6x
Sat, 19 Aug 2023SEK 50.6bSEK 9.1b-SEK 1,308,392,355.0082.1x-38.7x5.5x
Mon, 17 Jul 2023SEK 48.2bSEK 8.4b-SEK 1,693,182,186.0081.3x-28.5x5.8x
Wed, 14 Jun 2023SEK 48.2bSEK 8.4b-SEK 1,706,714,871.0077x-28.2x5.8x
Fri, 12 May 2023SEK 50.0bSEK 8.2b-SEK 1,783,532,568.0083.9x-28x6.1x
Sun, 09 Apr 2023SEK 46.4bSEK 8.0b-SEK 1,793,930,310.0088x-25.8x5.8x
Tue, 07 Mar 2023SEK 44.6bSEK 8.0b-SEK 1,791,847,360.0089.9x-24.9x5.6x
Thu, 02 Feb 2023SEK 47.6bSEK 7.3b-SEK 1,966,335,157.00280x-24.2x6.5x
Sat, 31 Dec 2022SEK 48.2bSEK 7.3b-SEK 1,910,765,999.00283.1x-25.2x6.6x
Price to Earnings Ratio

-25.2x


Total Market Cap: SEK 48.2bTotal Earnings: -SEK 1,910,765,999.00Total Revenue: SEK 7.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Pharma Industry Price to Earnings3Y Average -70.8x202320242025
Current Industry PE
  • Investors are relatively neutral on the Swedish Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 8.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 10% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market0.39%
Healthcare0.40%
Pharma0.022%
Pharma0.022%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CAMX CamurusSEK 606.502.0%
+SEK 715.7m		7.0%PE46.3x
SECARE SwedencareSEK 37.704.1%
+SEK 239.8m		-23.0%PE95.8x
ORX OrexoSEK 27.3011.9%
+SEK 99.6m		53.4%PS1.7x
CESSA CessatechDKK 15.2427.0%
+DKK 60.2m		20.0%PB21.5x
MOB Moberg PharmaSEK 10.0412.5%
+SEK 52.4m		-4.4%PS37.8x

Latest News

CAMX
SEK 606.50
Camurus
7D
2.0%
1Y
7.0%

CAMX: Positive Obesity Data Will Drive Future Upside Potential

Narrative Update on Camurus Analysts have modestly raised their price target on Camurus to reflect a fair value of approximately SEK 794 per share, citing sustained strong revenue growth expectations and robust long term profit margins as key drivers of the upward revision. What's in the News Reported positive topline Phase 1b results for CAM2056, a monthly FluidCrystal semaglutide, showing dose dependent reductions in body weight, A1c, and fasting glucose that were comparable to or exceeded weekly semaglutide, with similar or better efficacy in a shorter treatment period (Key Developments).
ENZY
SEK 1.91
Enzymatica
7D
8.9%
1Y
16.9%

Will Enzymatica (STO:ENZY) Spend Its Cash Wisely?

Dec 20
Will Enzymatica (STO:ENZY) Spend Its Cash Wisely?
CESSA
DKK 15.24
Cessatech
7D
27.0%
1Y
20.0%
CINPHA
SEK 18.60
Cinclus Pharma Holding
7D
1.2%
1Y
-7.2%
ANNX
SEK 19.00
Annexin Pharmaceuticals
7D
-1.6%
1Y
-57.9%
MOB
SEK 10.04
Moberg Pharma
7D
12.5%
1Y
-4.4%

MOB: Exclusive European Licensing Deal Will Drive Strong Future Share Upside

Analysts have marginally adjusted their price target on Moberg Pharma, reiterating a fair value of SEK 13.0 per share as they maintain their assumptions for discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News Karo Healthcare AB signs an exclusive licensing agreement with Moberg Pharma for the commercialisation of MOB-015 across 19 European markets, including all major EU countries and the United Kingdom, ensuring a coordinated launch under the Lamisil brand (Company announcement) The licensing deal grants Karo responsibility for marketing, distribution, and sales in 11 countries where MOB-015 is already approved but not yet launched, accelerating the product’s European rollout (Company announcement) MOB-015, a new topical terbinafine formulation, demonstrates mycological cure rates of 76 percent in registration studies, delivering efficacy on par with oral treatment and addressing historical challenges in penetrating the nail (Company announcement) The agreement provides Moberg Pharma with access to a total addressable population of about 500 million people in Europe, significantly expanding the commercial potential of MOB-015 (Company announcement) Valuation Changes Fair Value: Unchanged at SEK 13.0 per share, reflecting a stable outlook for Moberg Pharma’s intrinsic valuation.
ORX
SEK 27.30
Orexo
7D
11.9%
1Y
53.4%

ORX: New Science Park Facilities Will Support Stronger Long Term Prospects

Analysts have modestly raised their price target on Orexo to $31.00, highlighting a slightly richer future earnings multiple that is expected to offset a small anticipated erosion in long term profit margins. What's in the News Relocating to new, modern premises in Uppsala Science Park to support the next phase of the company’s development and growth (Key Developments) New facilities include laboratories, cleanrooms, and flexible office spaces designed to strengthen research and development capabilities (Key Developments) Site designed with a clear sustainability profile, featuring energy and cost efficient solutions to reduce environmental impact (Key Developments) Move aims to foster greater collaboration and innovation with partners, academia, healthcare providers, and patients (Key Developments) Valuation Changes Fair Value: Unchanged at SEK 31.0 per share, indicating no revision to the central valuation estimate.
FLERIE
SEK 36.35
Flerie
7D
-4.5%
1Y
-22.5%
SECARE
SEK 37.70
Swedencare
7D
4.1%
1Y
-23.0%
KDEV
SEK 0.43
Karolinska Development
7D
-4.4%
1Y
-56.2%
ODI
SEK 3.22
ODI Pharma
7D
67.7%
1Y
13.4%
KLAR
SEK 0.61
Klaria Pharma Holding AB (publ.)
7D
-10.8%
1Y
84.8%
CLBIO
SEK 16.35
Corline Biomedical
7D
-2.1%
1Y
84.5%
ALZCUR
SEK 2.08
AlzeCure Pharma
7D
-3.3%
1Y
74.8%
DICOT
SEK 0.32
Dicot Pharma
7D
-10.0%
1Y
46.3%
STABL
SEK 0.21
Stayble Therapeutics
7D
-15.6%
1Y
-48.5%